Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry
References (29)
- et al.
HER2 amplification ratios by fluorescence in-situ hybridisation and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues
Clin Breast Cancer
(2004) - et al.
Targeted therapy in breast cancer: the HER-2/neu gene and protein
Mol Cell Proteomics
(2004) - et al.
Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study
Breast
(2003) - et al.
The biology of erbB-2/neu/HER-2 and its role in cancer
Biochim Biophys Acta
(1994) - et al.
Overexpression of the c-erbB-2 oncogene: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?
Eur J Cancer
(1992) - et al.
Quantitation of EGFR and cerbB-2 expression in preinvasive compared to invasive breast cancer
Eur J Cancer
(1999) - et al.
Chromogenic in situ hybridisation: a practical alternative for fluorescence in situ hybridisation to detect HER-2/neu oncogene amplification in archival breast cancer samples
Am J Pathol
(2000) - et al.
Determination of HER2 gene amplification by chromogenic in-situ hybridisation (CISH) in archival breast carcinoma
Mod Pathol
(2002) - et al.
Chromogenic in-situ hybridisation: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in achival human breast carcinoma
Lab Invest
(2002) - et al.
Reliability of chromogenic in situ hybridisation for detecting HER2 gene status in breast cancer: comparison with fluorescence in situ hybridisation and assessment of interobserver reproducibility
Mod Pathol
(2005)
Amplification and overexpression of the neu oncogene in human breast carcinomas
Eur J Surg Oncol
Prognostic importance of c-erbB-2 expression in breast cancer
J Clin Oncol
Amplification of a novel c-erbB-related gene in a human mammary carcinoma
Science
HER2 as a prognostic factor in breast cancer.
Oncology
Cited by (44)
Quantification of protein-protein interactions and activation dynamics: A new path to predictive biomarkers
2022, Biophysical ChemistryCitation Excerpt :This led to the development of chromogenic in-situ hybridisation (CISH). This assay utilised a peroxidase-based chromogenic reaction to detect HER2 gene amplification, however, unlike FISH this was visualised on a standard brightfield microscope, allowing for the simultaneous assessment of tumour morphology [9]. Whilst this advancement of gene amplification detection was welcomed, there was still an unmet need for rapid oncogene profiling coupled with quantitative imaging.
The basics of immunohistochemistry
2020, In Situ Molecular Pathology and Co-expression AnalysesThe basics of in situ hybridization
2020, In Situ Molecular Pathology and Co-expression AnalysesThe biochemical basis of in situ hybridization and immunohistochemistry
2020, In Situ Molecular Pathology and Co-expression AnalysesEffectiveness of Silver-enhanced In Situ Hybridization for Evaluating HER2 Gene Status in Invasive Breast Carcinoma: A Comparative Study
2012, Archives of Medical ResearchCitation Excerpt :Moreover, FISH requires a learning curve, and only individuals experienced in FISH interpretation should read the slides due to misinterpretation of signal vs. noise, resulting in interobserver variability (12). CISH assay detects gene amplification and tissue morphologic features by using a peroxidase enzyme-labeled probe for chromogenic detection instead of a fluorescent dye (13,14). Results can be evaluated by using a standard brightfield microscope.